Kairos Pharma, LTD.

KAPA · NYSE · SIC 2834: Pharmaceutical Preparations
45
SEC Filings

Business Summary

Overview We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies to treat cancer. Our mission is to advance our portfolio of innovative therapeutics ...

Next Earnings

Q2 FY2026 — expected 2026-09-11

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionKAPAdiscussed_in_filing Cybersecurity
topic_mentionKAPAdiscussed_in_filing Trusted Computing
topic_mentionKAPAdiscussed_in_filing Blockchain & Crypto
topic_mentionKAPAdiscussed_in_filing Regulation
topic_mentionKAPAdiscussed_in_filing Healthcare & Bio
topic_mentionKAPAdiscussed_in_filing Networking
topic_mentionKAPAdiscussed_in_filing Cybersecurity
topic_mentionKAPAdiscussed_in_filing Trusted Computing
topic_mentionKAPAdiscussed_in_filing Blockchain & Crypto
topic_mentionKAPAdiscussed_in_filing Regulation
topic_mentionKAPAdiscussed_in_filing Healthcare & Bio
topic_mentionKAPAdiscussed_in_filing Networking
topic_mentionKAPAdiscussed_in_filing Cybersecurity
topic_mentionKAPAdiscussed_in_filing Trusted Computing
topic_mentionKAPAdiscussed_in_filing Blockchain & Crypto
topic_mentionKAPAdiscussed_in_filing Regulation
topic_mentionKAPAdiscussed_in_filing Healthcare & Bio
topic_mentionKAPAdiscussed_in_filing Networking
topic_mentionKAPAdiscussed_in_filing Cybersecurity
topic_mentionKAPAdiscussed_in_filing Trusted Computing

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-312025-12-310001493152-26-014159EDGAR109K words
2025-04-152024-12-310001641172-25-004920EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-142025-09-300001493152-25-023276EDGAR19K words
2025-08-122025-06-300001641172-25-023167EDGAR—
2025-05-142025-03-310001641172-25-010089EDGAR—
2024-11-142024-09-300001493152-24-045671EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-020001493152-26-008435EDGAR1K words
2026-02-260001493152-26-008116EDGAR—
2025-10-150001493152-25-018145EDGAR—
2025-10-070001493152-25-017208EDGAR—
2025-09-180001493152-25-013975EDGAR—
2025-09-110001493152-25-013040EDGAR—
2025-09-030001641172-25-026316EDGAR—
2025-07-150001641172-25-019645EDGAR—
2025-06-120001641172-25-014905EDGAR—
2025-06-030001641172-25-013368EDGAR—

45 total filings indexed. 29 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001962011
TickerKAPA
ExchangeNYSE
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: b372f9da8777939ed51f86459a6e35ac5764f2500778569a5fcfd198b2ca0744
parent: fa11b0cf71dc9d43ab85bd42e97234b3b4701c93a82de86a147cccf3b7e92bab
content hash: bbc8d1e66227973c7a5d8c64fa2214bd9551737244268a129d8452c84edf2e75
signed: 2026-04-13T04:45:51.297Z
sources: 6 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf